Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery of Molecular DNA Methylation-Based Biomarkers through Genome-Wide Analysis of Response Patterns to BCG for Bladder Cancer

5 Aug 2020

Abstract excerpt

Background: Bacillus Calmette-Guérin (BCG) immunotherapy, the standard adjuvant intravesical therapy for some intermediate and most high-risk non-muscle invasive bladder cancers (NMIBCs), suffers from a heterogenous response rate. Molecular markers to help guide responses are scarce and currently not used in the clinical setting. Methods: To identify novel biomarkers and pathways involved in response to BCG...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bladder and Urothelial Cancer Treatments
Share to Epigenetics and DNA Methylation
Share to Immune responses and vaccinations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32764425
DOI: 10.3390/cells9081839

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery of Molecular DNA Methylation-Based Biomarkers through Genome-Wide Analysis of Response Patterns to BCG for Bladder CancerPMID 32764425Read ↗

Immune profiles and DNA methylation alterations related with non-muscle-invasive bladder cancer outcomesSemantic proximity Read ↗

Proteogenomic characterization of the non-muscle-invasive bladder cancer response to BCG reveals potential therapeutic strategiesSemantic proximity Read ↗

Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non-Muscle-Invasive Bladder Cancer.Semantic proximity Read ↗

Establishment of a CIMP-associated prognostic model for bladder cancerSemantic proximity Read ↗

The Role of CXCL12-Mediated Aberrant Methylation and Tumor Microenvironment Remodeling in Carcinogenesis and Prognosis of Bladder CancerSemantic proximity Read ↗

Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets MeetSemantic proximity Read ↗

Genomic analysis of BCG unresponsive non-muscle-invasive bladder cancer identifies drivers of sensitivity to intravesical Gemcitabine/DocetaxelSemantic proximity Read ↗

Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.Semantic proximity Read ↗

Elevated T-cell exhaustion and urinary tumor DNA levels are associated with BCG failure in patients with non-muscle invasive bladder cancerSemantic proximity Read ↗

Tumor Immune Infiltration as a Predictor of Response to Neoadjuvant Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: An Integrative TCGA AnalysisSemantic proximity Read ↗

Quantitative genome-wide methylation analysis of high-grade non-muscle invasive bladder cancerSemantic proximity Read ↗

DNA Methylation Modification Map to Predict Tumor Molecular Subtypes and Efficacy of Immunotherapy in Bladder CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.